Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SALUTENSIN vs ALDORIL D50
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Salutensin is a combination of two antihypertensive agents: hydroflumethiazide, a thiazide diuretic that inhibits the Na+/Cl- symporter in the distal convoluted tubule, reducing sodium and water reabsorption; and reserpine, a Rauwolfia alkaloid that depletes catecholamines (norepinephrine, dopamine) from presynaptic nerve terminals by irreversibly blocking vesicular monoamine transporter (VMAT), leading to decreased peripheral vasoconstriction and heart rate.
Aldoril D50 is a combination of methyldopa and hydrochlorothiazide. Methyldopa is a centrally-acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume and further lowering blood pressure.
Hypertension
Hypertension (first-line or second-line therapy),Hypertensive urgency (off-label)
Oral, 1 tablet (50 mg spironolactone + 5 mg bendroflumethiazide) once daily. Maximum 2 tablets per day.
1 tablet (hydrochlorothiazide 25 mg + methyldopa 250 mg) orally twice daily; maximum dose: 2 tablets (50 mg + 500 mg) twice daily.
Terminal elimination half-life: 18-24 hours (mean 20 h); clinically, requires 5-7 days to reach steady state; prolonged in renal impairment (Cr Cl <30 m L/min: up to 40 h) and in elderly.
3–6 hours (terminal elimination half-life); clinical context: requires twice-daily dosing for sustained blood pressure control; prolonged in renal impairment.
Hydroflumethiazide: not extensively metabolized, mainly excreted unchanged in urine. Reserpine: extensively metabolized in the liver via hydrolysis and conjugation, with metabolites excreted in urine and feces.
Methyldopa is extensively metabolized in the liver via conjugation and O-methylation, with involvement of catechol-O-methyltransferase (COMT). Hydrochlorothiazide is not extensively metabolized; it is eliminated largely unchanged by the kidneys.
Primarily renal (65-75% as unchanged drug); biliary/fecal (20-30%) with enterohepatic recirculation; minor metabolism via CYP3A4 to inactive metabolites.
Renal: 50% as unchanged drug and 20% as metabolites; biliary/fecal: ~25% (as metabolites); total renal clearance accounts for ~70% of elimination.
98% bound to albumin and α1-acid glycoprotein; binding is concentration-independent; altered in hypoalbuminemia.
~20% bound to albumin; minimal binding to other plasma proteins.
0.15-0.25 L/kg (approx. 10-18 L in 70 kg adult); indicates moderate tissue distribution; Vd increased in hypertension (0.3 L/kg) and decreased in heart failure.
0.2–0.3 L/kg (moderately low Vd, indicating limited extravascular distribution and predominantly plasma water distribution).
Oral: 85-95% due to extensive absorption and minimal first-pass metabolism; food delays absorption but does not reduce extent; IV and IM: 100%.
Oral: 30–40% (due to extensive first-pass metabolism); IV: 100%.
Contraindicated if GFR <30 m L/min. If GFR 30-50 m L/min, reduce dose to half tablet daily and monitor potassium; avoid if potassium >5.5 mmol/L.
Contraindicated if GFR < 30 m L/min; for GFR 30-50 m L/min: reduce dose and monitor electrolytes.
Contraindicated in Child-Pugh class C. In class A or B, use with caution; start at half tablet daily and monitor hepatic function.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50% and monitor; Class C: contraindicated.
Not recommended for children under 18 years due to lack of safety data.
Not recommended; inadequate safety data.
Start at half tablet daily (25 mg spironolactone + 2.5 mg bendroflumethiazide). Monitor renal function, electrolytes, and blood pressure closely. Avoid if creatinine clearance <30 m L/min.
Start with 1 tablet (hydrochlorothiazide 12.5 mg + methyldopa 125 mg) once daily; increase slowly; monitor for hypotension and electrolyte imbalance.
Reserpine may cause mental depression. Therapy should be discontinued at the first sign of depression (e.g., despondency, early morning insomnia, loss of appetite, impotence). Depressive reactions are more common in patients with a history of depression.
None
Electrolyte imbalance (hypokalemia, hyponatremia), hypotension, drowsiness/sedation, depression risk, exacerbation of peptic ulcer or ulcerative colitis, use caution in renal/hepatic impairment, and avoid abrupt discontinuation (reserpine may cause withdrawal syndrome).
Sedation and drowsiness common; avoid driving or hazardous activities. Risk of Coombs-positive hemolytic anemia with methyldopa (discontinue if anemia develops). Hepatotoxicity and liver function abnormalities (discontinue if jaundice occurs). Orthostatic hypotension; caution in volume-depleted patients. Electrolyte imbalances (particularly hypokalemia, hyponatremia) with hydrochlorothiazide; monitor serum electrolytes. Sulfonamide cross-sensitivity possible. Exacerbation of systemic lupus erythematosus. Avoid abrupt withdrawal of methyldopa (may cause rebound hypertension).
Hypersensitivity to thiazides, reserpine, or sulfonamides; anuria or severe renal impairment; history of mental depression; active peptic ulcer; ulcerative colitis; pheochromocytoma; electroconvulsive therapy; concurrent MAO inhibitor therapy.
Active hepatic disease (cirrhosis, hepatitis) associated with methyldopa therapy; previous methyldopa-induced liver disorders. Anuria or hypersensitivity to thiazide diuretics or sulfonamide-derived drugs. Concomitant use with MAO inhibitors. Severe renal impairment (creatinine clearance <30 m L/min) or electrolyte depletion due to hydrochlorothiazide. Concurrent lithium therapy (risk of lithium toxicity).
Avoid high-sodium foods as they may reduce antihypertensive effect. Limit alcohol intake due to additive blood pressure lowering and dizziness risk. Ensure adequate potassium intake (e.g., bananas, oranges) unless contraindicated by renal function.
Avoid potassium supplements or salt substitutes containing potassium without consulting doctor. Limit alcohol intake. Avoid excessive grapefruit juice. Maintain adequate potassium intake through diet to prevent hypokalemia.
First trimester: Limited human data; based on animal studies, possible increased risk of congenital anomalies including cardiovascular and renal defects. Second and third trimesters: Risk of fetal hypotension, decreased placental perfusion, oligohydramnios, and neonatal renal dysfunction or failure. Avoid use in pregnancy unless no alternative.
Hydrochlorothiazide (HCTZ) is Pregnancy Category B in first trimester and Category D in second/third trimesters. Methyldopa (M) is Category B. HCTZ use in second/third trimester may cause fetal/neonatal effects including electrolyte disturbances, jaundice, thrombocytopenia, and possible fetal growth restriction. Methyldopa has not shown teratogenicity. Aldoril D50 (M 500mg/HCTZ 50mg) is not recommended during pregnancy, especially after first trimester.
Excreted into breast milk; M/P ratio not established. Potential for adverse effects in nursing infant (hypotension, bradycardia). Use with caution, monitor infant for signs of hypotension.
Both methyldopa and HCTZ are excreted in breast milk. Methyldopa M/P ratio approximately 1.0; HCTZ M/P ratio variable, small amounts. Use during breastfeeding may suppress lactation due to HCTZ diuretic effect. Monitor infant for signs of hypotension, electrolyte imbalance. Caution recommended; use only if clearly needed.
No specific dose adjustment studies; pregnancy may alter pharmacokinetics (increased volume of distribution, decreased plasma protein binding). Monitor therapeutic response and toxicity closely; consider dose titration based on blood pressure.
Pregnancy-induced increase in plasma volume may reduce effectiveness of HCTZ, requiring dose adjustment. Methyldopa pharmacokinetics not significantly altered; however, increased clearance in pregnancy may require higher doses. In preeclampsia, dose adjustments may be needed. Avoid HCTZ in pregnancy if possible.
SALUTENSIN is a combination of hydrochlorothiazide and reserpine. Monitor for hypokalemia and hyperuricemia due to thiazide; reserpine may cause nasal congestion and depression. Avoid in patients with history of depression or peptic ulcer. Use with caution in renal impairment (Cr Cl <30 m L/min).
ALDORIL D50 combines methyldopa and hydrochlorothiazide. Monitor for orthostatic hypotension, especially in volume-depleted patients. May cause positive Coombs test, hemolytic anemia, and lupus-like syndrome. Avoid in pheochromocytoma. Use caution in hepatic disease.
Take this medication exactly as prescribed, usually once daily in the morning to avoid nocturia.,Avoid sudden discontinuation; consult your doctor before stopping.,Report symptoms of depression, unusual mood changes, or nasal congestion to your healthcare provider.,This drug may cause dizziness or drowsiness; avoid driving until you know how it affects you.,Monitor for signs of low potassium (muscle cramps, weakness, irregular heartbeat) or high uric acid (joint pain, swelling).
Take exactly as prescribed; do not skip doses or double up.,May cause dizziness or drowsiness; avoid driving until you know how it affects you.,Report unexplained fever, jaundice, or dark urine immediately.,Avoid sudden discontinuation; may cause rapid increase in blood pressure.,Stay hydrated but do not overhydrate; monitor for signs of electrolyte imbalance.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SALUTENSIN vs ALDORIL D50, answered by our medical review team.
SALUTENSIN is a Antihypertensive Combination that works by Salutensin is a combination of two antihypertensive agents: hydroflumethiazide, a thiazide diuretic that inhibits the Na+/Cl- symporter in the distal convoluted tubule, reducing sodium and water reabsorption; and reserpine, a Rauwolfia alkaloid that depletes catecholamines (norepinephrine, dopamine) from presynaptic nerve terminals by irreversibly blocking vesicular monoamine transporter (VMAT), leading to decreased peripheral vasoconstriction and heart rate.. ALDORIL D50 is a Antihypertensive Combination that works by Aldoril D50 is a combination of methyldopa and hydrochlorothiazide. Methyldopa is a centrally-acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume and further lowering blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SALUTENSIN and ALDORIL D50 depend on the specific clinical indication. These are both Antihypertensive Combination agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SALUTENSIN is: Oral, 1 tablet (50 mg spironolactone + 5 mg bendroflumethiazide) once daily. Maximum 2 tablets per day.. The standard adult dose of ALDORIL D50 is: 1 tablet (hydrochlorothiazide 25 mg + methyldopa 250 mg) orally twice daily; maximum dose: 2 tablets (50 mg + 500 mg) twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SALUTENSIN and ALDORIL D50 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SALUTENSIN is classified as Category C. First trimester: Limited human data; based on animal studies, possible increased risk of congenital anomalies including cardiovascular and renal defects. Second and third trimester. ALDORIL D50 is classified as Category C. Hydrochlorothiazide (HCTZ) is Pregnancy Category B in first trimester and Category D in second/third trimesters. Methyldopa (M) is Category B. HCTZ use in second/third trimester ma. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.